Genotypic determinants of the virological response to tenofovir disoproxil fumarate in nucleoside reverse transcriptase inhibitor-experienced patients

Antiviral Therapy

Volumn 9, Issue 3, 2004, Pages 315-323

  Masquelier, Bernard ^a   Tamalet, Catherine ^b   Montès, Brigitte ^c   Descamps, Diane ^d   Peytavin, Gilles ^d   Bocket, Laurence ^e   Wirden, Marc ^f   Izopet, Jacques ^g   Schneider, Véronique ^h   Ferré, Virginie ⁱ   Ruffault, Annick ^j   Palmer, Pierre ^k   Trylesinski, Aldo ^l   Miller, Michael ^m   Brun Vézinet, Françoise ^d   Costagliola, Dominique ⁿ  

^a BORDEAUX UNIVERSITY HOSPITAL   (France)

^b TIMONE HOSPITAL   (France)

^c MONTPELLIER UNIVERSITY HOSPITAL   (France)

^d BICHAT HOSPITAL   (France)

^e LILLE UNIVERSITY HOSPITAL   (France)

^f PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^g TOULOUSE UNIVERSITY HOSPITAL   (France)

^h HÔPITAL TENON   (France)

ⁱ NANTES UNIVERSITY HOSPITAL   (France)

^j RENNES UNIVERSITY HOSPITAL   (France)

^k SAINT LOUIS HOSPITAL   (France)

^l Gilead Sciences   (France)

^m GILEAD SCIENCES   (United States)

ⁿ INSERM   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; AMPRENAVIR; DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; LOPINAVIR; NELFINAVIR; NEVIRAPINE; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TENOFOVIR DISOPROXIL; ZALCITABINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIVIRAL ACTIVITY; ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; DRUG POTENTIATION; EXPERIENCE; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; MULTICENTER STUDY; PRESCRIPTION; PREVALENCE; PRIORITY JOURNAL; SAMPLING; VIROLOGY; VIRUS LOAD;

ADENINE; CODON; COHORT STUDIES; FRANCE; GENOTYPE; HIV INFECTIONS; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; MULTIVARIATE ANALYSIS; PHOSPHONIC ACIDS; POINT MUTATION; REVERSE TRANSCRIPTASE INHIBITORS; RNA, VIRAL;

EID: 3042856914     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Meyer PR, Matsuura SE, So AG & Scott WA. Unblocking of chain-terminated primer by HIV-1 reverse transcriptase through a nucleotide-dependent mechanism. Proceedings of the National Academy of Sciences, USA 1998; 95:13471-13477.
2. Naeger LK, Margot NA & Miller MD. ATP-dependant removal of nucleoside reverse transcriptase inhibitors by human immunodeficiency virus type 1 reverse transcriptase. Antimicrobial Agents & Chemotherapy 2002; 46:2179-2184.
3. Staszewski S, Gallant JE, Pozniak AL, Suleiman JMAH, DeJesus E, Sayre J et al. Efficacy and safety of tenofovir DF vs. stavudine when used in combination with lamivudine and efavirenz in antiretroviral naive patients: 96-week preliminary interim results, 10th Conference on Retroviuses & Opportunistic Infections. Boston, Mass., USA, February 2003. Abstract 564b.
4. Margot NA, Isaacson E, McGowan I, Cheng AK, Schooley RT & Miller MD. Genotypic and phenotypic analyses of HIV-1 in antiretroviral-experience patients treated with tenofovir DF. AIDS 2002; 16:1227-1235.
5. Schooley RT, Ruane P, Myers RA, Beall G, Lampiris H, Berger D, Chen SS, Miller MD, Isaacson E & Cheng AK. Tenofovir DF in antiretroviral-experienced patients: results from a 48-week, randomized, double-blind study. AIDS 2002; 16:1257-1263.
6. Miller MD, Margot NA, Hertogs K, Larder B & Miller V. Antiviral activity of tenofovir (PMPA) against nucleoside-resistant HIV samples. 40th Interscience Conference on Antimicrobial Agents & Chemotherapy. Toronto, Canada, September 2000. Abstract 2115.
7. Wainberg MA, Miller MD, Quan Y, Salomon H, Mulato AS, Lamy PD, Margot NA, Anton KE & Cherrington JM. In vitro selection and characterization of HIV-1 with reduced susceptibility to PMPA. Antiviral Therapy 1999; 4:87-94.
8. Tuske S, Sarafianos S, Clark AD Jr, Ding J, Naeger LK, Miller MD, Gibbs C, Jerina M, Hughes S & Arnold E. Crystal structure of HIV-1 RT with template-primer terminated with the acyclic nucleotide RT inhibitor tenofovir suggests mechanisms of evading resistance. 9th Conference on Retroviruses & Opportunistic Infections. Seattle, Wash., USA, February 2002. Abstract 44.
9. Brun-Vézinet F, Descamps D, Ruffault A, Masquelier B, Calvez C, Peytavin G, Telles F, Morand-Joubert L, Meynard JL, Vray M, Costagliola D & the Narval (ANRS 088) Study Group. Clinically relevant interpretation of genotype for resistance to abacavir. AIDS 2003; 17:1795-1802.
10. Fleury H, Recordon-Pinson P, Caumont A, Faure M, Roques P, Plantier JC, Couturier E, Dormont D, Masquelier B, Simon F & the ANRS AC11 Laboratory Network. HIV type 1 diversity in France, 1999-2001: molecular characterization of non-B HIV type 1 subtypes and potential impact on susceptibility to antiretroviral drugs. AIDS Research & Human Retroviruses 2003; 19:41-47.
11. Brun-Vézinet F, Masquelier B, Izopet J, Calvez V, Chaix ML, Ruffault A, Tamalet C, Yerly S, Descamps D, Costagliola D & the ANRS Resistance Group. Quality control for HIV-I genotypic antiretroviral testing (2002). Antiviral Therapy 2003; 8:S101.
12. Gonzales MJ, Wu TD, Taylor J, Belitskaya I, Kantor R, Israelski D, Chou S, Zolopa AR, Fessel WJ & Shafer RW. Extended spectrum of HIV-1 reverse transcriptase mutations in patients receiving multiple nucleoside analog inhibitors. AIDS 2003; 17:791-799.
13. Cundy KC, Sueoka C, Lynch GR, Griffin L, Lee WA & Shaw JP. Pharmacokinetics and bioavailability of the anti-human immunodeficiency virus nucleotide analog 9-[(R)-2-(phosphonomethoxy)propyl]adenine (PMPA) in dogs. Antimicrobial Agents & Chemotherapy 1998; 42:687-690.
14. Barditch-Crovo P, Deeks SG, Collier A, Safrin S, Coakley F, Miller M, Kearney BP, Coleman RL, Lamy PD, Kahn JO, McGowan I & Lietman PS. Phase I/II trial of the pharmacokinetics, safety, and antiretroviral activity of tenofovir disoproxil fumarate in HIV-1 infected adults. Antimicrobial Agents & Chemotherapy 2001; 45:2733-2739.
15. Flaherty JF, Kearney BP, Wolf JJ, Sayre JR & Coakley. A multiple-dose, randomized, crossover drug interaction study between tenofovir DF and efavirenz, indinavir, or lopinavir/ritonavir. 1st IAS Conference on HIV Pathogenesis & Treatment. Buenos Aires, Argentina, July 2001. Abstract 336.
16. Miller MD, Margot NA & Lu B. Effect of baseline nucleoside-associated resistance on response to tenofovir DF (TDF) therapy: integrated analyses of studies 902 and 907. 9th Conference on Retroviruses & Opportunistic Infections. Seattle, Wash., USA, February 2002. Abstract 43.
17. Hanna GJ, Johnson VA, Kuritzkes DR, Richman DD, Brown AJ, Savara AV, Hazelwood JD & D'Aquila RT. Patterns of resistance mutations selected by treatment of human immunodeficiency virus type 1 infection with zidovudine, didanosine, and nevirapine. Journal of Infectious Diseases 2000; 181:904-911.
18. Yahi N, Tamalet C, Tourres C, Tivoli N & Fantini J. Mutation L210W of HIV-1 reverse transcriptase in patients receiving combination therapy. Incidence, association with other mutations, and effects on the structure of mutated reverse transcriptase. Journal of Biomedical Science 2000; 7:507-513.
19. Winters MA & Merigan TC. Variants other than aspartic acid at codon 69 of the human immunodeficiency virus type 1 reverse transcriptase gene affect susceptibility to nucleoside analogs. Antimicrobial Agents & Chemotherapy 2001; 45:2276-2279.
20. St Clair MH, Martin JL, Tudor-Williams G, Bach MC, Vavro CL, King DM, Kellam P, Kemp SD & Larder BA. Resistance to ddI and sensitivity to AZT induced by a mutation in HIV reverse transcriptase. Science 1991; 253:1557-1559.
21. Margot NA, Cheng AK, Lu B & Miller MD. Expanded response analyses of tenofovir DF therapy by baseline resistance genotype and phenotype. 14th International AIDS Conference. Barcelona, Spain, July 2002. Abstract ThOrB1390.
22. Lamotte C, Kirstetter M, Landman R, Lariven S, Reynes J, Katlama C & Peytavin G. Elevated didanosine (ddI) plasma concentrations in HIV-infected patients treated by a tenofovir disoproxil fumarate (TDF)-enteric coated (EC)-ddI containing regimen. 4th International Workshop on Clinical Pharmacology of HIV Therapy. Cannes, France, March 2003. Abstract 8.6.
23. Kearney BP, Damle B, Plummer A, Sayre J, Namini H, Ryan K & Cheng AK. Pharmacokinetic evaluation of tenofovir DF and enteric-coated didanosine. 14th International AIDS Conference. Barcelona, Spain, July 2002. Abstract LBPeB9026.
24. Kearney BP, Flaherty JF, Wolf JJ, Barrier S, Wong S, Chen SS, Wolfsohn M, Sayre J & Coakley DE Coadministration of tenofovir DF and didanosine: pharmacokinetic drug-drug interaction and safety evaluation. 8th European Conference on Clinical Aspects & Treatment of HIV Infection. Athens, Greece, October 2001. Abstract 172.